
ICCM Stock Forecast & Price Target
ICCM Analyst Ratings
Bulls say
Icecure Medical Ltd is positioned for a positive growth trajectory, with anticipated topline sales improvement expected in the first half of 2026, supported by potential FDA marketing authorization for their ProSense cryoablation system aimed at breast cancer by 2025. The successful De Novo clearance aligns with expectations and highlights the effectiveness of Icecure's liquid nitrogen-based cryoablation technology as a minimally invasive treatment for low-risk, early-stage breast cancer. Additionally, a narrower net loss of $3.6 million, compared to an expected $4.4 million, reflects improved operational efficiency, bolstering confidence in the company's financial health moving forward.
Bears say
IceCure Medical Ltd reported a revenue of $725K for 1Q25, reflecting a 2% decline year-over-year, primarily driven by decreased sales in Asia despite growth in Europe and North America. There are substantial concerns regarding the commercial viability of its cryoablation systems, with risks including potential failure to achieve market success due to competition, market size limitations, and penetration rates. Additionally, the company faces dilution risks and challenges related to securing regulatory approval in the U.S., further contributing to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Icecure Medical Ltd and is not a guaranteed prediction by Public.com or investment advice.
ICCM Analyst Forecast & Price Prediction
Start investing in ICCM
Order type
Buy in
Order amount
Est. shares
0 shares